Page last updated: 2024-11-10

gamma-linolenic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

gamma-Linolenic Acid: An omega-6 fatty acid produced in the body as the delta 6-desaturase metabolite of linoleic acid. It is converted to dihomo-gamma-linolenic acid, a biosynthetic precursor of monoenoic prostaglandins such as PGE1. (From Merck Index, 11th ed) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

gamma-linolenic acid : A C18, omega-6 acid fatty acid comprising a linolenic acid having cis- double bonds at positions 6, 9 and 12. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5280933
CHEMBL ID464982
CHEBI ID28661
SCHEMBL ID19418
MeSH IDM0027133

Synonyms (118)

Synonym
BRD-K18059238-001-02-1
6-cis,9-cis,12-cis-octadecatrienoic acid
(z,z,z)-6,9,12-octadecatrienoic acid
(6,9,12)-linolenic acid
c18:3 (n-6)
octadeca-6,9,12-triensaeure
cis-delta(6,9,12)-octadecatrienoic acid
18:3 (n-6)
gamoleic acid
gamma-linolensaeure
CHEBI:28661 ,
c18:3, n-6,9,12 all-cis
all-cis-6,9,12-octadecatrienoic acid
epogam
efamast
acido gamolenico [spanish]
gamolenic acid [inn:ban]
acide gamolenique [french]
acidum gamolenicum [latin]
BSPBIO_001338
gamolenic acid (inn)
D07213
gamma linolenic acid
IDI1_033808
6(z),9(z),12(z)-octadecatrienoic acid
ccris 7668
6,9,12-octadecatrienoic acid, (6z,9z,12z)-
6,9,12-all-cis-octadecatrienoic acid
cis-6,cis-9,cis-12-octadecatrienoic acid
6,9,12-octadecatrienoic acid, (z,z,z)-
cis,cis,cis-6,9,12-octadecatrienoic acid
C06426
gamolenic acid
gamma-linolenic acid
(6z,9z,12z)-octadecatrienoic acid
506-26-3
ligla
(6z,9z,12z)-octadeca-6,9,12-trienoic acid
cis,cis,cis,6,9,12-octa-decatrienoic acid-18:3 n6 lithium salt
gamma-linolenic acid, >=99%, liquid
NCGC00160469-01
cis-6, cis-9, cis-12-octadecatrienoic acid
c18:3n-6,9,12
6z,9z,12z-octadecatrienoic acid
gammolenic acid
LMFA01030141
NCGC00160469-03
NCGC00160469-02
NCGC00160469-04
smr000058609
MLS001333661
MLS001333662
HMS1989C20
D58CCA4A-7FFA-4E8B-A758-EAA7D073B343
octadecatrienoic acid, 6,9,12-(z,z,z)-
BML3-B06
gamma-linolenic acid (18:3 n-6)
HMS1791C20
HMS1361C20
bdbm50269532
L0152
gamolenic-acid
gammalinolenic acid
CHEMBL464982 ,
.gamma.-linolenic acid
(6z,9z,12z-octadecatrienoic acid
18:3(n-6)
delta-linolenic acid
ndi 609
sonova 400
tox21_111835
cas-506-26-3
dtxsid7046170 ,
dtxcid5026170
HMS2230A18
acide gamolenique
acidum gamolenicum
acido gamolenico
unii-78yc2max4o
78yc2max4o ,
(6z,9z,12z)-6,9,12-octadecatrienoic acid
ndi 609 [fdms]
gamolenic acid [mart.]
gamolenic acid [inn]
.gamma.-linolenic acid [mi]
gamolenic acid [who-dd]
gamma-linolenic acid (constituent of spirulina) [dsc]
S5743
gtpl4710
c18:3,n-6
AKOS022175367
z,z,z-octadeca-6,9,12-trienoic acid
z,z,z-6,9,12-octadecatrienoic acid
gamma-linoleic acid
SCHEMBL19418
AC-33785
HMS3649H09
HMS3402C20
mfcd00065718
gamma-linolenic acid, analytical standard
(z,z,z)-6,9,12-octadecatrienoate
gamma-llnolenic acid
6(z),9(z),12(z)-octadecatrienoate
6,9,12-octadecatrienoate
6,9,12-all-cis-octadecatrienoate
Q415885
c18h30o2 (cis,cis,cis-octadeca-6,9,12-trienoic acid)
DB13854
DS-10685
sr-01000838334
SR-01000838334-2
gamma-linolenic-acid
CS-W012291
HY-N7140
A871498
gamma -linolenic acid (18:3, n-6)
y-linolenic acid
EN300-7420515

Research Excerpts

Toxicity

gamma-linolenic acid appears to be a safe and efficient additional therapy for infants and young children. The evening primrose oil-derived omega-6 fatty acid arachidonic acid inhibits sodium ion currents and synaptic transmission. The night primroseOil-derived eicosanoid prostaglandin E(1) appears to have anticonvulsant activity.

ExcerptReferenceRelevance
" Dietetic and pharmacological approaches are the basis of the treatment of atopic dermatitis and gamma-linolenic acid appears to be a safe and efficient additional therapy for infants and young children."( The efficacy and safety of gamma-linolenic acid in the treatment of infantile atopic dermatitis.
Agostoni, C; Banderali, G; Fiocchi, A; Riva, E; Sala, M; Signoroni, P,
)
0.65
" Current trends in the treatment of human tumors are for drug combinations that result in improved responses as well as the ability to use less toxic concentrations of the drugs."( Omega-6 polyunsaturated fatty acid gamma-linolenic acid (18:3n-6) enhances docetaxel (Taxotere) cytotoxicity in human breast carcinoma cells: Relationship to lipid peroxidation and HER-2/neu expression.
Colomer, R; Lupu, R; Menendez, JA; Ropero, S, 2004
)
0.6
" Taken as whole, the toxic effect of the FA on insulin-producing RINm5F cells varied irrespective of the chain length and the degree of unsaturation."( Fatty acid-induced toxicity and neutral lipid accumulation in insulin-producing RINm5F cells.
Azevedo-Martins, AK; Curi, R; Lenzen, S; Lima, CL; Monteiro, AP, 2006
)
0.33
" Not only are linoleic acid and gamma-linolenic acid safe in epilepsy, with prolonged oral administration of linoleic acid and alpha-linolenic acid (in a 4:1 mixture) protecting rats from having seizures in four different epilepsy models, but the evening primrose oil-derived omega-6 fatty acid arachidonic acid inhibits sodium ion currents and synaptic transmission, while the evening primrose oil-derived eicosanoid prostaglandin E(1) appears to have anticonvulsant activity."( The safety of evening primrose oil in epilepsy.
Puri, BK, 2007
)
0.62

Pharmacokinetics

ExcerptReferenceRelevance
"Defects in the metabolism of gamma-linolenic acid are thought to play a major role in the pathogenesis of atopic eczema, but little is known about the pharmacokinetic behavior of this fatty acid and its metabolic products."( Pharmacokinetic data of gamma-linolenic acid in healthy volunteers after the administration of evening primrose oil (Epogam).
Martens-Lobenhoffer, J; Meyer, FP, 1998
)
0.9
" Pharmacokinetic analyses indicated that fasting plasma GLA and EPA levels plateaued within 7 days' daily consumption at all levels of intake, whereas the time to maximum plasma concentration (Tmax) was shorter for GLA than for EPA."( Inhibition of leukotriene synthesis, pharmacokinetics, and tolerability of a novel dietary fatty acid formulation in healthy adult subjects.
Chilton, FH; Edens, MB; Koumenis, IL; Surette, ME; Tramposch, KM, 2003
)
0.32

Compound-Compound Interactions

ExcerptReferenceRelevance
"The effects of gamma-linolenic acid-rich borage oil (BO), in combination with different marine oils, namely an eicosapentaenoic acid (EPA) rich oil (MO) or a DHA-rich oil (TO), on tissue fatty acid composition and prostaglandin production were investigated in turbot, a species which lacks appreciable delta5 fatty acyl desaturase activity."( Effects of dietary gamma-linolenic acid-rich borage oil combined with marine fish oils on tissue phospholipid fatty acid composition and production of prostaglandins E and F of the 1-, 2- and 3-series in a marine fish deficient in delta5 fatty acyl desatu
Bell, JG; Farndale, BM; Sargent, JR; Tocher, DR, 1997
)
0.98

Bioavailability

ExcerptReferenceRelevance
" Gamma-linolenic acid (GLA) and catechins bioavailability and their effects on skin functionality have not been previously investigated from a fermented dairy product."( Consumption of functional fermented milk containing borage oil, green tea and vitamin E enhances skin barrier function.
Blachon, JL; Guyonnet, D; Lassel, T; Puch, F; Rawlings, AV; Samson-Villeger, S, 2008
)
1.26
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Of 60 patients with atopic dermatitis (30 males and 30 females, 15-30 years old) 30 were treated with gamma-linolenic acid of (C18:3 n-6) at a dosage of 274 mg twice a day; the other 30 patients were given placebo.

ExcerptRelevanceReference
" Bolus dosing significantly increased parameters of mucosal mass along the length of the small intestine in association with an increase in two hour accumulation of vincristine arrested metaphases in small intestinal crypts."( Effects of bolus doses of fat on small intestinal structure and on release of gastrin, cholecystokinin, peptide tyrosine-tyrosine, and enteroglucagon.
Bloom, SR; Ghatei, MA; Jenkins, AP; Thompson, RP, 1992
)
0.28
" Dosage may be crucial; 8 Efamol capsules per day were used in this study."( Gamma-linolenic acid for attention-deficit hyperactivity disorder: placebo-controlled comparison to D-amphetamine.
Arnold, LE; Kleykamp, D; Kontras, SB; Taylor, WA; Tobin, K; Votolato, NA, 1989
)
1.72
" In parallel experiments, cycling naive vascular SMC isolated from nonpurified diet-fed mice were dosed with exogenous prostaglandin E1 (PGE1 ) for various periods and challenged with cycloheximide for 4 h (8-12 h after PGE1 addition), and intracellular cAMP levels were measured at various time points."( Dietary gamma-linolenic acid enhances mouse macrophage-derived prostaglandin E1 which inhibits vascular smooth muscle cell proliferation.
Chapkin, RS; Fan, YY; Ramos, KS, 1997
)
0.73
"Of 60 patients with atopic dermatitis (30 males and 30 females, 15-30 years old) 30 were treated with gamma-linolenic acid of (C18:3 n-6) at a dosage of 274 mg twice a day; the other 30 patients were given placebo."( Efficacy of gamma-linolenic acid in the treatment of patients with atopic dermatitis.
Abate, G; Amerio, P; Andreassi, M; Di Lorio, A; Forleo, P; Masci, S,
)
0.73
"The n-6 EFA effects on tumour ROIs were analysed in terms of kinetics, dose-response and individual cell type responses using flow cytometry of intracellular 2',7'-dichlorofluorescin oxidation."( Dynamics of reactive oxygen intermediate production in human glioma: n-6 essential fatty acid effects.
Gregor, A; Ironside, JW; Leaver, HA; Miller, EP; Prescott, RJ; Su, BH; Whittle, IR; Williams, JR, 1999
)
0.3
" For both GLA salts, cytotoxicity was manifested after 4 days of cell exposure and with very sharp dose-response curves."( Cytotoxic effects of two gamma linoleic salts (lithium gammalinolenate or meglumine gammalinolenate) alone or associated with a nitrosourea: an experimental study on human glioblastoma cell lines.
Bryce, R; Etienne, MC; Ferrero, JM; Fischel, JL; Formento, P; Ilc, K; Milano, G, 1999
)
0.3
"The dose-response patterns were similar for all four glioma spheroids."( Effects of N-6 essential fatty acids on glioma invasion and growth: experimental studies with glioma spheroids in collagen gels.
Bell, HS; Leaver, HA; Wharton, SB; Whittle, IR, 1999
)
0.3
"The atopic mothers were randomly assigned to low (n=10) or high (n=10) dosage oral supplementation with oral borage oil for one week (230 or 460 mg gamma-linolenic acid (18:3n-6) per day)."( Essential fatty acids in breast milk of atopic mothers: comparison with non-atopic mothers, and effect of borage oil supplementation.
Houwelingen, A; Mordant, A; Poorterman, I; Thijs, C; van den Brandt, P, 2000
)
0.51
"There appears to be some potential benefit for the use of GLA in rheumatoid arthritis although further studies are required to establish optimum dosage and duration of treatment."( Herbal therapy for treating rheumatoid arthritis.
Little, C; Parsons, T, 2001
)
0.31
" The effects, clinical studies, side effects, and dosing regimens for aloe vera, arnica, black cohosh, evening primrose oil, and saw palmetto are described."( Therapeutic use of selected herbs.
Cohen, SM; Robinson, EH; Rousseau, ME, 2000
)
0.31
" Full thickness human skin was dosed with 500 microl saturated solution of tamoxifen in borage oil (25% GLA) and the simultaneous permeation of the two actives determined."( Simultaneous permeation of tamoxifen and gamma linolenic acid across excised human skin. Further evidence of the permeation of solvated complexes.
Harwood, JL; Heard, CM; Karia, C; Morris, AP, 2004
)
0.32
" Owners of the dogs recorded pruritus daily using a 10 cm visual analog scale and the dosage of prednisolone was established based on the pruritus score, according to written instructions."( A randomized, controlled study to evaluate the steroid sparing effect of essential fatty acid supplementation in the treatment of canine atopic dermatitis.
Bergvall, K; Hedhammar, A; Holm, BR; Kristensen, F; Larsen, S; Saevik, BK; Saijonmaa-Koulumies, LE, 2004
)
0.32
" CLA at the dosage used in this study was not efficacious in treating canine AD, whereas BSO may help some dogs with AD, although further studies are necessary before this can be recommended as a treatment."( Conjugated linoleic acid and black currant seed oil in the treatment of canine atopic dermatitis: a preliminary report.
Banni, S; Carta, G; Cordeddu, L; Melis, MP; Murru, E; Noli, C, 2007
)
0.34
" The DGLA levels in the liver, serum, and brain significantly increased with increasing dosage of DGLA in the diet."( Distribution and metabolism of dihomo-gamma-linolenic acid (DGLA, 20:3n-6) by oral supplementation in rats.
Fujiwara, Y; Kawashima, H; Kiso, Y; Matsumoto, A; Morimitsu, Y; Ono, Y; Sagawa, S; Seyama, Y; Umeda-Sawada, R; Ushiyama, I, 2006
)
0.6
" The differences in the overall levels of GLA suggest the accumulation of the novel fatty acid was not limited by a lack of incorporation into the triacylgylcerol backbone (>66% GLA achieved), or correlated with gene dosage (GLA levels independent of gene copy number), but rather reflected the differences in Δ6-desaturase activity from the two sources."( High level accumulation of gamma linolenic acid (C18:3Δ6.9,12 cis) in transgenic safflower (Carthamus tinctorius) seeds.
Boothe, JG; Fidantsef, A; Harry, I; Moloney, MM; Nykiforuk, CL; Oinam, GS; Reed, C; Shewmaker, C; Yurchenko, OP; Zaplachinski, S; Zhang, M, 2012
)
0.38
" There is a need for adequately powered, well-planned and well-conducted randomized trials to give clear recommendations on the individual utility and dosage of intravenous omega-3 fatty acids in critical illness."( Intravenous fish oil in adult intensive care unit patients.
Heller, AR, 2015
)
0.42
"The optimal preparation of Oenothera biennis oil solid lipid nanoparticles was as follows: Oenothera biennis dosage 300 mg, glycerol monostearate-Oenothera biennis (2: 3), Oenothera biennis -RH/40/PEG-400 (1: 2), RH-40/PEG-400 (1: 2)."( [Preparation of Oenothera biennis Oil Solid Lipid Nanoparticles Based on Microemulsion Technique].
Cui, YL; Jin, Y; Piao, LM; Yin, SY, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
linolenic acidA two-membered subclass of octadecatrienoic acid comprising the (9Z,12Z,15Z)- and (6Z,9Z,12Z)-isomers. Linolenic acids are nutrients essential to the formation of prostaglandins and are also used in making paints and synthetic resins.
omega-6 fatty acidA family of polyunsaturated fatty acids that have in common a final carbon-carbon double bond in the n-6 position, i.e., the sixth bond from the methyl end of the fatty acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (404)

PathwayProteinsCompounds
Alpha Linolenic Acid and Linoleic Acid Metabolism517
Triacylglycerol Degradation TG(16:0/16:0/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(16:0/18:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(16:0/18:1(9Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(16:0/18:1(11Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(16:0/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(16:0/18:3(6Z,9Z,12Z)/16:0)512
Triacylglycerol Degradation TG(16:0/18:3(6Z,9Z,12Z)/18:0)513
Triacylglycerol Degradation TG(16:0/18:3(6Z,9Z,12Z)/18:1(9Z))513
Triacylglycerol Degradation TG(16:0/18:3(6Z,9Z,12Z)/18:1(11Z))513
Triacylglycerol Degradation TG(16:0/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(16:0/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(16:0/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(16:0/18:3(6Z,9Z,12Z)/20:0)513
Triacylglycerol Degradation TG(16:0/18:3(6Z,9Z,12Z)/20:1(11Z))513
Triacylglycerol Degradation TG(16:0/18:3(6Z,9Z,12Z)/20:1(13Z))512
Triacylglycerol Degradation TG(16:0/18:3(6Z,9Z,12Z)/22:0)513
Triacylglycerol Degradation TG(16:0/18:3(6Z,9Z,12Z)/22:1(13Z))513
Triacylglycerol Degradation TG(16:0/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(16:0/20:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(16:0/20:1(11Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(16:0/20:1(13Z)/18:3(6Z,9Z,12Z))59
Triacylglycerol Degradation TG(16:0/22:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(16:0/22:1(13Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:0/16:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:0/18:0/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:0/18:1(9Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:0/18:1(11Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:0/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:0/18:3(6Z,9Z,12Z)/16:0)512
Triacylglycerol Degradation TG(18:0/18:3(6Z,9Z,12Z)/18:0)512
Triacylglycerol Degradation TG(18:0/18:3(6Z,9Z,12Z)/18:1(9Z))513
Triacylglycerol Degradation TG(18:0/18:3(6Z,9Z,12Z)/18:1(11Z))513
Triacylglycerol Degradation TG(18:0/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:0/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:0/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:0/18:3(6Z,9Z,12Z)/20:0)513
Triacylglycerol Degradation TG(18:0/18:3(6Z,9Z,12Z)/20:1(11Z))513
Triacylglycerol Degradation TG(18:0/18:3(6Z,9Z,12Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:0/18:3(6Z,9Z,12Z)/22:0)513
Triacylglycerol Degradation TG(18:0/18:3(6Z,9Z,12Z)/22:1(13Z))513
Triacylglycerol Degradation TG(18:0/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:0/20:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:0/20:1(11Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:0/20:1(13Z)/18:3(6Z,9Z,12Z))59
Triacylglycerol Degradation TG(18:0/22:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:0/22:1(13Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/16:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:1(9Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:1(11Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:3(6Z,9Z,12Z)/16:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(6Z,9Z,12Z)/18:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(6Z,9Z,12Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(6Z,9Z,12Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:3(6Z,9Z,12Z)/20:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(6Z,9Z,12Z)/20:1(11Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:3(6Z,9Z,12Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(6Z,9Z,12Z)/22:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(6Z,9Z,12Z)/22:1(13Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/20:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/20:1(11Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/20:1(13Z)/18:3(6Z,9Z,12Z))59
Triacylglycerol Degradation TG(18:1(9Z)/22:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/22:1(13Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(11Z)/16:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:1(9Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:1(11Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:1(11Z)/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:3(6Z,9Z,12Z)/16:0)512
Triacylglycerol Degradation TG(18:1(11Z)/18:3(6Z,9Z,12Z)/18:0)512
Triacylglycerol Degradation TG(18:1(11Z)/18:3(6Z,9Z,12Z)/18:1(9Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:3(6Z,9Z,12Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:1(11Z)/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:1(11Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:3(6Z,9Z,12Z)/20:0)512
Triacylglycerol Degradation TG(18:1(11Z)/18:3(6Z,9Z,12Z)/20:1(11Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:3(6Z,9Z,12Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:1(11Z)/18:3(6Z,9Z,12Z)/22:0)512
Triacylglycerol Degradation TG(18:1(11Z)/18:3(6Z,9Z,12Z)/22:1(13Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(11Z)/20:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(11Z)/20:1(11Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(11Z)/20:1(13Z)/18:3(6Z,9Z,12Z))59
Triacylglycerol Degradation TG(18:1(11Z)/22:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(11Z)/22:1(13Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/16:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:1(9Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:1(11Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)/16:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)/18:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)/20:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)/20:1(11Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)/22:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)/22:1(13Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:1(11Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:1(13Z)/18:3(6Z,9Z,12Z))59
Triacylglycerol Degradation TG(18:2(9Z,12Z)/22:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/22:1(13Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/16:0/16:0)511
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/16:0/18:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/16:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/16:0/18:1(11Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/16:0/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/16:0/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/16:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/16:0/20:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/16:0/20:1(11Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/16:0/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/16:0/22:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/16:0/22:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:0/16:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:0/18:0)511
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:0/18:1(11Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:0/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:0/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:0/20:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:0/20:1(11Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:0/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:0/22:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:0/22:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(9Z)/16:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(9Z)/18:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(9Z)/18:1(9Z))511
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(9Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(9Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(9Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(9Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(9Z)/20:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(9Z)/20:1(11Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(9Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(9Z)/22:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(9Z)/22:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(11Z)/16:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(11Z)/18:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(11Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(11Z)/18:1(11Z))511
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(11Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(11Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(11Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(11Z)/20:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(11Z)/20:1(11Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(11Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(11Z)/22:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(11Z)/22:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:2(9Z,12Z)/16:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:2(9Z,12Z)/18:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:2(9Z,12Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:2(9Z,12Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:2(9Z,12Z)/18:2(9Z,12Z))511
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:2(9Z,12Z)/20:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:2(9Z,12Z)/20:1(11Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:2(9Z,12Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:2(9Z,12Z)/22:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:2(9Z,12Z)/22:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/16:0)511
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/18:0)511
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/18:1(9Z))511
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/18:1(11Z))511
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))511
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))511
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/20:0)511
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/20:1(11Z))511
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/20:1(13Z))511
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/22:0)511
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/22:1(13Z))511
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/16:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/18:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/20:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/20:1(11Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/22:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/22:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:0/16:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:0/18:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:0/18:1(11Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:0/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:0/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:0/20:0)511
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:0/20:1(11Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:0/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:0/22:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:0/22:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(11Z)/16:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(11Z)/18:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(11Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(11Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(11Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(11Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(11Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(11Z)/20:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(11Z)/20:1(11Z))511
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(11Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(11Z)/22:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(11Z)/22:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(13Z)/16:0)59
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(13Z)/18:0)59
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(13Z)/18:1(9Z))59
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(13Z)/18:1(11Z))59
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(13Z)/18:2(9Z,12Z))59
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(13Z)/18:3(6Z,9Z,12Z))58
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(13Z)/18:3(9Z,12Z,15Z))59
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(13Z)/20:0)59
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(13Z)/20:1(11Z))59
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(13Z)/20:1(13Z))58
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(13Z)/22:0)59
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(13Z)/22:1(13Z))59
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:0/16:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:0/18:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:0/18:1(11Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:0/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:0/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:0/20:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:0/20:1(11Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:0/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:0/22:0)511
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:0/22:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:1(13Z)/16:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:1(13Z)/18:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:1(13Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:1(13Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:1(13Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:1(13Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:1(13Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:1(13Z)/20:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:1(13Z)/20:1(11Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:1(13Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:1(13Z)/22:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:1(13Z)/22:1(13Z))511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/16:0/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:0/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(9Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(11Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/16:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/18:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/20:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/20:1(11Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/22:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/22:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:0/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(11Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(13Z)/18:3(6Z,9Z,12Z))59
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:0/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:1(13Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(20:0/16:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(20:0/18:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(20:0/18:1(9Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(20:0/18:1(11Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(20:0/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(20:0/18:3(6Z,9Z,12Z)/16:0)512
Triacylglycerol Degradation TG(20:0/18:3(6Z,9Z,12Z)/18:0)512
Triacylglycerol Degradation TG(20:0/18:3(6Z,9Z,12Z)/18:1(9Z))513
Triacylglycerol Degradation TG(20:0/18:3(6Z,9Z,12Z)/18:1(11Z))513
Triacylglycerol Degradation TG(20:0/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(20:0/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(20:0/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(20:0/18:3(6Z,9Z,12Z)/20:0)512
Triacylglycerol Degradation TG(20:0/18:3(6Z,9Z,12Z)/20:1(11Z))513
Triacylglycerol Degradation TG(20:0/18:3(6Z,9Z,12Z)/20:1(13Z))512
Triacylglycerol Degradation TG(20:0/18:3(6Z,9Z,12Z)/22:0)513
Triacylglycerol Degradation TG(20:0/18:3(6Z,9Z,12Z)/22:1(13Z))513
Triacylglycerol Degradation TG(20:0/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(20:0/20:0/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(20:0/20:1(11Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(20:0/20:1(13Z)/18:3(6Z,9Z,12Z))59
Triacylglycerol Degradation TG(20:0/22:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(20:0/22:1(13Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(20:1(11Z)/16:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(20:1(11Z)/18:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(20:1(11Z)/18:1(9Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(20:1(11Z)/18:1(11Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(20:1(11Z)/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(20:1(11Z)/18:3(6Z,9Z,12Z)/16:0)512
Triacylglycerol Degradation TG(20:1(11Z)/18:3(6Z,9Z,12Z)/18:0)512
Triacylglycerol Degradation TG(20:1(11Z)/18:3(6Z,9Z,12Z)/18:1(9Z))512
Triacylglycerol Degradation TG(20:1(11Z)/18:3(6Z,9Z,12Z)/18:1(11Z))512
Triacylglycerol Degradation TG(20:1(11Z)/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(20:1(11Z)/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(20:1(11Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(20:1(11Z)/18:3(6Z,9Z,12Z)/20:0)512
Triacylglycerol Degradation TG(20:1(11Z)/18:3(6Z,9Z,12Z)/20:1(11Z))512
Triacylglycerol Degradation TG(20:1(11Z)/18:3(6Z,9Z,12Z)/20:1(13Z))512
Triacylglycerol Degradation TG(20:1(11Z)/18:3(6Z,9Z,12Z)/22:0)512
Triacylglycerol Degradation TG(20:1(11Z)/18:3(6Z,9Z,12Z)/22:1(13Z))513
Triacylglycerol Degradation TG(20:1(11Z)/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(20:1(11Z)/20:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(20:1(11Z)/20:1(11Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(20:1(11Z)/20:1(13Z)/18:3(6Z,9Z,12Z))59
Triacylglycerol Degradation TG(20:1(11Z)/22:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(20:1(11Z)/22:1(13Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(20:1(13Z)/16:0/18:3(6Z,9Z,12Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:0/18:3(6Z,9Z,12Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:1(9Z)/18:3(6Z,9Z,12Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:1(11Z)/18:3(6Z,9Z,12Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(6Z,9Z,12Z)/16:0)511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(6Z,9Z,12Z)/18:0)511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(6Z,9Z,12Z)/18:1(9Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(6Z,9Z,12Z)/18:1(11Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))510
Triacylglycerol Degradation TG(20:1(13Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(6Z,9Z,12Z)/20:0)511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(6Z,9Z,12Z)/20:1(11Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(6Z,9Z,12Z)/20:1(13Z))510
Triacylglycerol Degradation TG(20:1(13Z)/18:3(6Z,9Z,12Z)/22:0)511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(6Z,9Z,12Z)/22:1(13Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))511
Triacylglycerol Degradation TG(20:1(13Z)/20:0/18:3(6Z,9Z,12Z))511
Triacylglycerol Degradation TG(20:1(13Z)/20:1(11Z)/18:3(6Z,9Z,12Z))511
Triacylglycerol Degradation TG(20:1(13Z)/20:1(13Z)/18:3(6Z,9Z,12Z))58
Triacylglycerol Degradation TG(20:1(13Z)/22:0/18:3(6Z,9Z,12Z))511
Triacylglycerol Degradation TG(20:1(13Z)/22:1(13Z)/18:3(6Z,9Z,12Z))511
Triacylglycerol Degradation TG(22:0/16:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(22:0/18:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(22:0/18:1(9Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(22:0/18:1(11Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(22:0/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(22:0/18:3(6Z,9Z,12Z)/16:0)512
Triacylglycerol Degradation TG(22:0/18:3(6Z,9Z,12Z)/18:0)512
Triacylglycerol Degradation TG(22:0/18:3(6Z,9Z,12Z)/18:1(9Z))513
Triacylglycerol Degradation TG(22:0/18:3(6Z,9Z,12Z)/18:1(11Z))513
Triacylglycerol Degradation TG(22:0/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(22:0/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(22:0/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(22:0/18:3(6Z,9Z,12Z)/20:0)512
Triacylglycerol Degradation TG(22:0/18:3(6Z,9Z,12Z)/20:1(11Z))513
Triacylglycerol Degradation TG(22:0/18:3(6Z,9Z,12Z)/20:1(13Z))512
Triacylglycerol Degradation TG(22:0/18:3(6Z,9Z,12Z)/22:0)512
Triacylglycerol Degradation TG(22:0/18:3(6Z,9Z,12Z)/22:1(13Z))513
Triacylglycerol Degradation TG(22:0/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(22:0/20:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(22:0/20:1(11Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(22:0/20:1(13Z)/18:3(6Z,9Z,12Z))59
Triacylglycerol Degradation TG(22:0/22:0/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(22:0/22:1(13Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(22:1(13Z)/16:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(22:1(13Z)/18:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(22:1(13Z)/18:1(9Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(22:1(13Z)/18:1(11Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(22:1(13Z)/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(22:1(13Z)/18:3(6Z,9Z,12Z)/16:0)512
Triacylglycerol Degradation TG(22:1(13Z)/18:3(6Z,9Z,12Z)/18:0)512
Triacylglycerol Degradation TG(22:1(13Z)/18:3(6Z,9Z,12Z)/18:1(9Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:3(6Z,9Z,12Z)/18:1(11Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(22:1(13Z)/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(22:1(13Z)/18:3(6Z,9Z,12Z)/20:0)512
Triacylglycerol Degradation TG(22:1(13Z)/18:3(6Z,9Z,12Z)/20:1(11Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:3(6Z,9Z,12Z)/20:1(13Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:3(6Z,9Z,12Z)/22:0)512
Triacylglycerol Degradation TG(22:1(13Z)/18:3(6Z,9Z,12Z)/22:1(13Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(22:1(13Z)/20:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(22:1(13Z)/20:1(11Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(22:1(13Z)/20:1(13Z)/18:3(6Z,9Z,12Z))59
Triacylglycerol Degradation TG(22:1(13Z)/22:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(22:1(13Z)/22:1(13Z)/18:3(6Z,9Z,12Z))512
Metabolism of alpha-linolenic acid615
Omega-3 / omega-6 fatty acid synthesis038
Linoleic acid metabolism affected by SARS-CoV-2513
Mitochondrial beta-oxidation064
Elongation of (very) long chain fatty acids345
Omega-3 and omega-6 unsaturated fatty acids biosynthesis pathway014

Protein Targets (28)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency20.24660.044717.8581100.0000AID485294; AID485341
glp-1 receptor, partialHomo sapiens (human)Potency31.62280.01846.806014.1254AID624417
thioredoxin reductaseRattus norvegicus (Norway rat)Potency70.79460.100020.879379.4328AID588453
WRNHomo sapiens (human)Potency35.48130.168331.2583100.0000AID651768
USP1 protein, partialHomo sapiens (human)Potency79.43280.031637.5844354.8130AID504865
GLS proteinHomo sapiens (human)Potency35.48130.35487.935539.8107AID624170
thioredoxin glutathione reductaseSchistosoma mansoniPotency28.18380.100022.9075100.0000AID485364
regulator of G-protein signaling 4Homo sapiens (human)Potency50.11870.531815.435837.6858AID504845
isocitrate dehydrogenase 1, partialHomo sapiens (human)Potency50.11876.309627.099079.4328AID602179
estrogen nuclear receptor alphaHomo sapiens (human)Potency21.31380.000229.305416,493.5996AID743069
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency35.48130.035520.977089.1251AID504332
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency48.02240.354828.065989.1251AID504847
chromobox protein homolog 1Homo sapiens (human)Potency79.43280.006026.168889.1251AID540317
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency23.71010.000323.4451159.6830AID743065
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency29.93490.168316.404067.0158AID720504
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency44.66840.425612.059128.1838AID504891
DNA polymerase eta isoform 1Homo sapiens (human)Potency25.04200.100028.9256213.3130AID588591; AID720502
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency53.41320.050127.073689.1251AID588590; AID720496
lethal(3)malignant brain tumor-like protein 1 isoform IHomo sapiens (human)Potency35.48130.075215.225339.8107AID485360
DNA polymerase kappa isoform 1Homo sapiens (human)Potency31.69640.031622.3146100.0000AID588579; AID720501
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency3.21970.005612.367736.1254AID624032
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency14.12540.251215.843239.8107AID504327
Cellular tumor antigen p53Homo sapiens (human)Potency33.49150.002319.595674.0614AID651631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TrypsinSus scrofa (pig)IC50 (µMol)200.00000.50000.50000.5000AID402793
Coagulation factor VIIHomo sapiens (human)IC50 (µMol)30.00000.00020.83363.3000AID402795
Tissue factorHomo sapiens (human)IC50 (µMol)30.00000.00010.734410.0000AID402795
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Free fatty acid receptor 1Homo sapiens (human)EC50 (µMol)4.62000.00030.73698.8000AID1275404
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Caspase 6, apoptosis-related cysteine peptidaseHomo sapiens (human)AC500.50500.063611.235844.9700AID720632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (165)

Processvia Protein(s)Taxonomy
phospholipase C-activating G protein-coupled receptor signaling pathwayFree fatty acid receptor 1Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationFree fatty acid receptor 1Homo sapiens (human)
insulin secretionFree fatty acid receptor 1Homo sapiens (human)
negative regulation of interleukin-1 beta productionFree fatty acid receptor 1Homo sapiens (human)
glucose homeostasisFree fatty acid receptor 1Homo sapiens (human)
positive regulation of calcium ion transportFree fatty acid receptor 1Homo sapiens (human)
response to fatty acidFree fatty acid receptor 1Homo sapiens (human)
ion channel modulating, G protein-coupled receptor signaling pathwayFree fatty acid receptor 1Homo sapiens (human)
ligand-gated ion channel signaling pathwayFree fatty acid receptor 1Homo sapiens (human)
positive regulation of insulin secretionFree fatty acid receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayFree fatty acid receptor 1Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
response to hypoxiaCoagulation factor VIIHomo sapiens (human)
positive regulation of leukocyte chemotaxisCoagulation factor VIIHomo sapiens (human)
blood coagulationCoagulation factor VIIHomo sapiens (human)
circadian rhythmCoagulation factor VIIHomo sapiens (human)
response to carbon dioxideCoagulation factor VIIHomo sapiens (human)
positive regulation of platelet-derived growth factor receptor signaling pathwayCoagulation factor VIIHomo sapiens (human)
protein processingCoagulation factor VIIHomo sapiens (human)
positive regulation of blood coagulationCoagulation factor VIIHomo sapiens (human)
positive regulation of cell migrationCoagulation factor VIIHomo sapiens (human)
animal organ regenerationCoagulation factor VIIHomo sapiens (human)
positive regulation of TOR signalingCoagulation factor VIIHomo sapiens (human)
response to estradiolCoagulation factor VIIHomo sapiens (human)
response to vitamin KCoagulation factor VIIHomo sapiens (human)
response to genisteinCoagulation factor VIIHomo sapiens (human)
response to estrogenCoagulation factor VIIHomo sapiens (human)
positive regulation of positive chemotaxisCoagulation factor VIIHomo sapiens (human)
response to growth hormoneCoagulation factor VIIHomo sapiens (human)
response to cholesterolCoagulation factor VIIHomo sapiens (human)
response to thyroxineCoagulation factor VIIHomo sapiens (human)
response to Thyroid stimulating hormoneCoagulation factor VIIHomo sapiens (human)
response to 2,3,7,8-tetrachlorodibenzodioxineCoagulation factor VIIHomo sapiens (human)
response to astaxanthinCoagulation factor VIIHomo sapiens (human)
response to thyrotropin-releasing hormoneCoagulation factor VIIHomo sapiens (human)
positive regulation of gene expressionTissue factorHomo sapiens (human)
positive regulation of interleukin-8 productionTissue factorHomo sapiens (human)
positive regulation of endothelial cell proliferationTissue factorHomo sapiens (human)
activation of plasma proteins involved in acute inflammatory responseTissue factorHomo sapiens (human)
activation of blood coagulation via clotting cascadeTissue factorHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processTissue factorHomo sapiens (human)
blood coagulationTissue factorHomo sapiens (human)
positive regulation of platelet-derived growth factor receptor signaling pathwayTissue factorHomo sapiens (human)
protein processingTissue factorHomo sapiens (human)
positive regulation of cell migrationTissue factorHomo sapiens (human)
positive regulation of TOR signalingTissue factorHomo sapiens (human)
positive regulation of angiogenesisTissue factorHomo sapiens (human)
positive regulation of positive chemotaxisTissue factorHomo sapiens (human)
cytokine-mediated signaling pathwayTissue factorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (43)

Processvia Protein(s)Taxonomy
G protein-coupled receptor activityFree fatty acid receptor 1Homo sapiens (human)
lipid bindingFree fatty acid receptor 1Homo sapiens (human)
bioactive lipid receptor activityFree fatty acid receptor 1Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
serine-type endopeptidase activityCoagulation factor VIIHomo sapiens (human)
signaling receptor bindingCoagulation factor VIIHomo sapiens (human)
calcium ion bindingCoagulation factor VIIHomo sapiens (human)
protein bindingCoagulation factor VIIHomo sapiens (human)
serine-type peptidase activityCoagulation factor VIIHomo sapiens (human)
serine-type endopeptidase activityTissue factorHomo sapiens (human)
protease bindingTissue factorHomo sapiens (human)
protein bindingTissue factorHomo sapiens (human)
phospholipid bindingTissue factorHomo sapiens (human)
cytokine receptor activityTissue factorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (30)

Processvia Protein(s)Taxonomy
plasma membraneFree fatty acid receptor 1Homo sapiens (human)
plasma membraneFree fatty acid receptor 1Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
extracellular regionCoagulation factor VIIHomo sapiens (human)
endoplasmic reticulum lumenCoagulation factor VIIHomo sapiens (human)
Golgi lumenCoagulation factor VIIHomo sapiens (human)
plasma membraneCoagulation factor VIIHomo sapiens (human)
vesicleCoagulation factor VIIHomo sapiens (human)
collagen-containing extracellular matrixCoagulation factor VIIHomo sapiens (human)
serine-type peptidase complexCoagulation factor VIIHomo sapiens (human)
extracellular spaceCoagulation factor VIIHomo sapiens (human)
extracellular spaceTissue factorHomo sapiens (human)
plasma membraneTissue factorHomo sapiens (human)
external side of plasma membraneTissue factorHomo sapiens (human)
cell surfaceTissue factorHomo sapiens (human)
membraneTissue factorHomo sapiens (human)
collagen-containing extracellular matrixTissue factorHomo sapiens (human)
serine-type peptidase complexTissue factorHomo sapiens (human)
plasma membraneTissue factorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (31)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID720501qHTS for Inhibitors of Polymerase Kappa: Confirmatory Assay for Cherry-picked Compounds2012PloS one, , Volume: 7, Issue:10
A comprehensive strategy to discover inhibitors of the translesion synthesis DNA polymerase κ.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID402799Inhibition of amidolytic activity of human recombinant soluble tissue factor/human factor 7a preincubated with tissue factor for 15 mins1998Journal of natural products, Nov, Volume: 61, Issue:11
Inhibitory activity of unsaturated fatty acids and anacardic acids toward soluble tissue factor-factor VIIa complex.
AID697033Inhibition of FASN in human SKBR3 cells at 179 uM2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
The lipogenesis pathway as a cancer target.
AID402794Octanol-water partition coefficient, log P of the compound1998Journal of natural products, Nov, Volume: 61, Issue:11
Inhibitory activity of unsaturated fatty acids and anacardic acids toward soluble tissue factor-factor VIIa complex.
AID402795Inhibition of amidolytic activity of human tissue factor/human factor 7a1998Journal of natural products, Nov, Volume: 61, Issue:11
Inhibitory activity of unsaturated fatty acids and anacardic acids toward soluble tissue factor-factor VIIa complex.
AID1275404Agonist activity at human FFAR1 expressed in CHO-K1 cells assessed as calcium flux measured for 100 secs by FLIPR assay2016European journal of medicinal chemistry, Feb-15, Volume: 109Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists.
AID402797Inhibition of amidolytic activity of human recombinant soluble tissue factor/human factor 7a preincubated with factor 7a for 15 mins1998Journal of natural products, Nov, Volume: 61, Issue:11
Inhibitory activity of unsaturated fatty acids and anacardic acids toward soluble tissue factor-factor VIIa complex.
AID402798Inhibition of amidolytic activity of human recombinant soluble tissue factor/human factor 7a preincubated with factor 7a for 90 mins1998Journal of natural products, Nov, Volume: 61, Issue:11
Inhibitory activity of unsaturated fatty acids and anacardic acids toward soluble tissue factor-factor VIIa complex.
AID402800Inhibition of amidolytic activity of human recombinant soluble tissue factor/human factor 7a preincubated with tissue factor for 90 mins1998Journal of natural products, Nov, Volume: 61, Issue:11
Inhibitory activity of unsaturated fatty acids and anacardic acids toward soluble tissue factor-factor VIIa complex.
AID402793Inhibition of pig pancreatic trypsin after 15 mins1998Journal of natural products, Nov, Volume: 61, Issue:11
Inhibitory activity of unsaturated fatty acids and anacardic acids toward soluble tissue factor-factor VIIa complex.
AID402796Inhibition of amidolytic activity of human recombinant soluble tissue factor (Ala-TF 1 to 219)/human factor 7a1998Journal of natural products, Nov, Volume: 61, Issue:11
Inhibitory activity of unsaturated fatty acids and anacardic acids toward soluble tissue factor-factor VIIa complex.
AID697032Inhibition of FASN in human SKBR3 cells at 22.4 uM2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
The lipogenesis pathway as a cancer target.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,217)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990182 (14.95)18.7374
1990's417 (34.26)18.2507
2000's322 (26.46)29.6817
2010's215 (17.67)24.3611
2020's81 (6.66)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 106.33

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index106.33 (24.57)
Research Supply Index7.32 (2.92)
Research Growth Index4.70 (4.65)
Search Engine Demand Index202.53 (26.88)
Search Engine Supply Index2.06 (0.95)

This Compound (106.33)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials216 (16.62%)5.53%
Reviews125 (9.62%)6.00%
Case Studies16 (1.23%)4.05%
Observational0 (0.00%)0.25%
Other943 (72.54%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]